Screening for Primary Aldosteronism by Mass Spectrometry Versus Immunoassay Measurements of Aldosterone: A Prospective Within-Patient Study
Open Access
- 27 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 9 (4) , 752-766
Abstract
Measurements of aldosterone by mass spectrometry are more accurate and less prone to interferences than immunoassay measurements, and may produce a more accurate aldosterone:renin ratio (ARR) when screening for primary aldosteronism (PA). Differences in diagnostic performance of the ARR using mass spectrometry vs immunoassay measurements of aldosterone were examined in 710 patients screened for PA. PA was confirmed in 153 patients and excluded in 451 others. Disease classifications were not achieved in 106 patients. Areas under receiver-operating characteristic curves (AUROC) and other measures were used to compare diagnostic performance. Mass spectrometry-based measurements yielded lower plasma aldosterone concentrations than immunoassay measurements. For the ARR based on immunoassay measurements of aldosterone, AUROCs were slightly lower (P = 0.018) than those using mass spectrometry measurements (0.895 vs 0.906). The cutoff for the ARR to reach a sensitivity of 95% was 30 and 21.5 pmol/mU by respective immunoassay and mass spectrometry-based measurements, which corresponded to specificities of 57% for both. With data restricted to patients with unilateral PA, diagnostic sensitivities of 94% with specificities >81% could be achieved at cutoffs of 61 and 52 pmol/mU for respective immunoassay and mass spectrometry measurements. Mass spectrometry-based measurements of aldosterone for the ARR provide no clear diagnostic advantage over immunoassay-based measurements. Both approaches offer limited diagnostic accuracy for the ARR as a screening test. One solution is to employ the higher cutoffs to triage patients likely to have unilateral PA for further tests and possible adrenalectomy, while using the lower cutoffs to identify others for targeted medical therapy. German Clinical Trials Register ID: DRKS00017084.Keywords
This publication has 40 references indexed in Scilit:
- Quantitation of Aldosterone in Serum or Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)2022
- Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interferenceClinica Chimica Acta, 2020
- Screening for primary aldosteronism using the newly developed IDS-iSYS® automated assay systemPractical Laboratory Medicine, 2017
- An LC–MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronismThe Journal of Steroid Biochemistry and Molecular Biology, 2015
- Enhancement of specificity of aldosterone measurement in human serum and plasma using 2D-LC–MS/MS and comparison with commercial immunoassaysJournal of Chromatography B, 2014
- Combination of LC–MS/MS aldosterone and automated direct renin in screening for primary aldosteronismClinica Chimica Acta, 2014
- Quantitation of aldosterone in human plasma by ultra high performance liquid chromatography tandem mass spectrometryJournal of Chromatography B, 2013
- Bias in estimating accuracy of a binary screening test with differential disease verificationStatistics in Medicine, 2011
- Determination of aldosterone in serum by liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2008
- A Screening Test to Identify Aldosterone-Producing Adenoma by Measuring Plasma Renin ActivityArchives of internal medicine (1960), 1981